Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Depreciation & Amortization (CF) (2016 - 2025)

Editas Medicine (EDIT) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $721000.0 as the latest value for Q3 2025.

  • Quarterly Depreciation & Amortization (CF) fell 54.91% to $721000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Sep 2025, down 0.85% year-over-year, with the annual reading at $5.8 million for FY2024, 4.35% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $721000.0 at Editas Medicine, down from $1.8 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $1.9 million in Q1 2025, with the low at $721000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $1.5 million, with a median of $1.5 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) surged 45.74% in 2021, then plummeted 54.91% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $1.6 million in 2021, then grew by 1.22% to $1.6 million in 2022, then dropped by 7.04% to $1.5 million in 2023, then dropped by 6.41% to $1.4 million in 2024, then plummeted by 47.45% to $721000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $721000.0, $1.8 million, and $1.9 million for Q3 2025, Q2 2025, and Q1 2025 respectively.